SCHEMBL3884151

SCHEMBL3884151

CCN(CC)c1nc(-c2cc(OC)ccc2OC)nc(N2CCN(c3ccccn3)CC2)n1

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.50
KDM4E B2RXH2 4/20 0.50
L3MBTL1 Q9Y468 2/20 0.50
LMNA P02545 3/20 0.49
SIGMAR1 Q99720 1/20 0.44
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
HTR1A P08908 2/20 0.43
HTR2A P28223 1/20 0.43
HTR2C P28335 1/20 0.43
HSD17B10 Q99714 4/20 0.43
USP2 O75604 1/20 0.43
HPGD P15428 2/20 0.43
CYP1A2 P05177 1/20 0.43
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43
NPSR1 Q6W5P4 1/20 0.42
CDK5 Q00535 1/20 0.42
CDK5R1 Q15078 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5451394 0.84 MAPT (0.59) ALDH1A1KDM4EL3MBTL1LMNAMEN1
SCHEMBL3879137 0.79 MAPT (0.44) ALDH1A1KDM4ELMNAMEN1KMT2A
SCHEMBL3887120 0.73 ALDH1A1 (0.56) ALDH1A1KDM4EL3MBTL1LMNAMEN1
SCHEMBL3888354 0.71 PIK3CA (0.48) ALDH1A1KDM4EL3MBTL1LMNAMEN1
SCHEMBL3243327 0.70 ALDH1A1 (0.48) ALDH1A1KDM4EL3MBTL1LMNAMEN1
SCHEMBL3883981 0.70 TRPA1 (0.49) KDM4EL3MBTL1HSD17B10USP2HPGD
SCHEMBL5442152 0.69 MAPK1 (0.58) ALDH1A1KDM4ELMNAMEN1KMT2A
SCHEMBL5456665 0.69 MAPK1 (0.46) ALDH1A1KDM4ELMNAMEN1KMT2A
SCHEMBL3889427 0.68 NTSR1 (0.45) ALDH1A1KDM4EL3MBTL1LMNAKMT2A
SCHEMBL3888946 0.67 PIK3CA (0.57) ALDH1A1KDM4EL3MBTL1LMNAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7566712-B2 Biaryl piperazinyl-pyridine analogues NEUROGEN CORPORATION (US) 2009-07-28 US claimed
US-7566712-B2 Biaryl piperazinyl-pyridine analogues NEUROGEN CORPORATION (US) 2009-07-28 US disclosed
US-7566712-B2 Biaryl piperazinyl-pyridine analogues NEUROGEN CORPORATION (US) 2009-07-28 US disclosed
US-7566712-B2 Biaryl piperazinyl-pyridine analogues NEUROGEN CORPORATION (US) 2009-07-28 US disclosed
US-20070027155-A1 Biaryl piperazinyl-pyridine analogues NEUROGEN CORPORATION 2007-02-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070027155-A1 Biaryl piperazinyl-pyridine analogues GPR174, GPR68, PPARG ALDH1A1 920/4885KDM4E 3890/4885L3MBTL1 4028/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.